2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 796

Presentation and Outcome of Large-Vessel Vasculitis Diagnosed between 50 and 60 Years: Case-Control Study Based on 183 Cases
Abstract Number: 1290

Preterm Birth Phenotypes in Women with Autoimmune Diseases
Abstract Number: 1291

Preterm Delivery Phenotypes in SLE Pregnancies
Abstract Number: 809

Prevalence and Distribution of Vascular FDG Uptake on Positron Emission Tomography (PET)-CT in Patients Suspected of Having Giant Cell Arteritis – Interim Results from the Giant Cell Arteritis and PET Scan (GAPS) Study
Abstract Number: 266

Prevalence and Pattern of Hand Osteoarthritis in a Working Population Using Ultrasound
Abstract Number: 1969

Prevalence and Predictive Value over 16 Years of Serum Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies in the General Population
Abstract Number: 1595

Prevalence and Predictors of Depression in Patients with Systemic Lupus Erythematosus: Results from the Korean Lupus Network (KORNET) Registry
Abstract Number: 1050

Prevalence and Predictors of Knee Replacement Overuse and Underuse in the US
Abstract Number: 1771

Prevalence and Prognostic Relevance of Cardiovascular Involvement in ANCA-Associated Vasculitis: A Retrospective Cohort Study
Abstract Number: 2515

Prevalence and Risk Factors for Osteoporotic Fractures and Low Bone Mineral Density in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis
Abstract Number: 711

Prevalence and Risk Factors of Depressive Disorders in Chinese Patients with Systemic Lupus Erythematosus (SLE)
Abstract Number: 2510

Prevalence of and Factors Associated with Sarcopenia in Patients of Ankylosing Spondylitis
Abstract Number: 8L

Prevalence of Blindness in a Cohort of Rheumatologic Patients Treated with Hydroxychloroquine
Abstract Number: 2883

Prevalence of Cardiovascular Risk Factors and Subclinical Cardovacular Disease in Psoriatic Arthritis
Abstract Number: 1122

Prevalence of Chronic Kidney Disease and Uncontrolled Serum Uric Acid Levels in US Adult Gout Population: Results from the National Health and Nutrition Examination Survey 2007–2012

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].